J Kurian1, J Mathew1, K Sowjanya1, K R K Chaitanya1, M Ramesh2, J Sebastian1, D Narayanappa3. 1. Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Mysore, Karnataka, 570015, India. 2. Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Mysore, Karnataka, 570015, India. madhanramesh@hotmail.com. 3. Department of Pediatrics, JSS Medical College and Hospital, JSS University, Mysore, Karnataka, India.
Abstract
OBJECTIVES: To determine the incidence, pattern, causality, preventability, severity and predictors of adverse drug reactions (ADRs) in pediatric population. METHODS: It was a prospective, observational study that included patients of either sex, of any age treated in the pediatric wards of a tertiary care hospital. Study patients were followed throughout their hospital stay. Whenever an ADR was detected, all the required data was collected and analyzed. Data was analyzed for incidence, causality (by using WHO Probability scale and Naranjo's algorithm), preventability (by using Modified Shumock and Thornton scale), severity (by using Modified Hartwig and Siegel scale) and predictors of ADRs. RESULTS: Of the 1775 children admitted in the pediatrics ward, 1082 patients met study criteria and were enrolled into the study. A total of 64 ADRs were identified from 54 patients. The incidence of ADRs was 4.99 %. Male patients experienced majority (68.52 %) of ADRs. Drugs most commonly implicated in ADRs were amoxicillin + clavulanate (21.87 %) followed by ceftriaxone (20.31 %). Most (51.56 %) of the ADRs reported belonged to the system organ class, gastrointestinal system disorders. Among the ADRs reported, 82.85 % of ADRs were mild. Majority (87.5 %) of the ADRs were of 'probable' causality category and 96.9 % were not preventable. There was a significant association between occurrence of ADRs and the use of ≥4 number of medications, age (infants) and gender (male). CONCLUSIONS: Among the pediatric population, infants, male gender and those receiving ≥4 number of medications are at risk of developing ADRs. Constant monitoring is required to address the safety issue in pediatric population especially in infants and patients receiving ≥4 drugs.
OBJECTIVES: To determine the incidence, pattern, causality, preventability, severity and predictors of adverse drug reactions (ADRs) in pediatric population. METHODS: It was a prospective, observational study that included patients of either sex, of any age treated in the pediatric wards of a tertiary care hospital. Study patients were followed throughout their hospital stay. Whenever an ADR was detected, all the required data was collected and analyzed. Data was analyzed for incidence, causality (by using WHO Probability scale and Naranjo's algorithm), preventability (by using Modified Shumock and Thornton scale), severity (by using Modified Hartwig and Siegel scale) and predictors of ADRs. RESULTS: Of the 1775 children admitted in the pediatrics ward, 1082 patients met study criteria and were enrolled into the study. A total of 64 ADRs were identified from 54 patients. The incidence of ADRs was 4.99 %. Male patients experienced majority (68.52 %) of ADRs. Drugs most commonly implicated in ADRs were amoxicillin + clavulanate (21.87 %) followed by ceftriaxone (20.31 %). Most (51.56 %) of the ADRs reported belonged to the system organ class, gastrointestinal system disorders. Among the ADRs reported, 82.85 % of ADRs were mild. Majority (87.5 %) of the ADRs were of 'probable' causality category and 96.9 % were not preventable. There was a significant association between occurrence of ADRs and the use of ≥4 number of medications, age (infants) and gender (male). CONCLUSIONS: Among the pediatric population, infants, male gender and those receiving ≥4 number of medications are at risk of developing ADRs. Constant monitoring is required to address the safety issue in pediatric population especially in infants and patients receiving ≥4 drugs.
Entities:
Keywords:
ADR monitoring; Adverse drug reactions; Pediatrics; Pharmacovigilance
Authors: Antje Neubert; Harald Dormann; Jutta Weiss; Tobias Egger; Manfred Criegee-Rieck; Wolfgang Rascher; Kay Brune; Burkhard Hinz Journal: Drug Saf Date: 2004 Impact factor: 5.606
Authors: Anke A G Posthumus; Carien C W Alingh; Christian C M Zwaan; Kees K van Grootheest; Lidwien L M Hanff; Bregje B C M Witjes; Geert W 't Jong; Matthijs de Hoog Journal: BMJ Open Date: 2012-08-24 Impact factor: 2.692
Authors: Ruairi M Gallagher; Jennifer R Mason; Kim A Bird; Jamie J Kirkham; Matthew Peak; Paula R Williamson; Anthony J Nunn; Mark A Turner; Munir Pirmohamed; Rosalind L Smyth Journal: PLoS One Date: 2012-12-04 Impact factor: 3.240
Authors: Jennifer R Bellis; Jamie J Kirkham; Signe Thiesen; Elizabeth J Conroy; Louise E Bracken; Helena L Mannix; Kim A Bird; Jennifer C Duncan; Matthew Peak; Mark A Turner; Rosalind L Smyth; Anthony J Nunn; Munir Pirmohamed Journal: BMC Med Date: 2013-11-07 Impact factor: 8.775
Authors: Gillian A Beauchamp; Alexandra Amaducci; Marna Rayl Greenberg; Matthew Meyers; Matthew Cook; Robert D Cannon; Kenneth D Katz; Yaron Finkelstein Journal: J Med Toxicol Date: 2019-07-15
Authors: Sheila Feitosa Ramos; Fernando de Castro Araújo-Neto; Giulyane Targino Aires-Moreno; Dyego Carlos Souza Anacleto de Araújo; Elisângela da Costa Lima; Divaldo Pereira de Lyra Journal: Int J Clin Pharm Date: 2021-03-03
Authors: Alexis E Horace; Negar Golchin; Elia M Pestana Knight; Neal V Dawson; Xuan Ma; James A Feinstein; Hannah K Johnson; Lawrence Kleinman; Paul M Bakaki Journal: Paediatr Drugs Date: 2020-02 Impact factor: 3.022
Authors: Karin M Egberts; Manfred Gerlach; Christoph U Correll; Paul L Plener; Uwe Malzahn; Peter Heuschmann; Stefan Unterecker; Maike Scherf-Clavel; Hans Rock; Gisela Antony; Wolfgang Briegel; Christian Fleischhaker; Alexander Häge; Tobias Hellenschmidt; Harmut Imgart; Michael Kaess; Andreas Karwautz; Michael Kölch; Karl Reitzle; Tobias Renner; Su-Yin Reuter-Dang; Christian Rexroth; Gerd Schulte-Körne; Frank M Theisen; Susanne Walitza; Christoph Wewetzer; Stefanie Fekete; Regina Taurines; Marcel Romanos Journal: Pharmacopsychiatry Date: 2022-02-07 Impact factor: 2.544